Serum angiopoietin-like protein 2 as a potential biomarker for diagnosis, early recurrence and prognosis in gastric cancer patients

Gastric cancer patients and healthy controls (192 tissue specimens; screening cohort: 32 GC patients, 23 healthy controls; validation cohort: 194 GC patients, 45 healthy controls) and human gastric cancer cell lines.

Measurement of serum and tissue ANGPTL2 expression; siRNA knockdown of ANGPTL2 in vitro.

Healthy controls and normal gastric mucosa.

Diagnostic accuracy (AUC) for distinguishing GC patients from healthy controls, tumor progression, early recurrence, and prognosis.surrogate